International Kidney Cancer Symposium | Conference

Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCC

November 4th 2022

Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.

Deep Responses Demonstrate Association With Prolonged Survival to Nivolumab/Cabozantinib in mRCC

November 4th 2022

Patients with treatment-naïve advanced renal cell carcinoma who received nivolumab plus cabozantinib achieved deeper objective responses leading to improved progression-free survival and overall survival rates vs those who received sunitinib, according to exploratory data from the CheckMate 9ER trial.

Lenvatinib Plus Everolimus Under Investigation Vs Cabozantinib in PD-1–Pretreated mRCC

November 4th 2022

The combination of lenvatinib plus everolimus is under evaluation vs cabozantinib in the phase 2 LenCabo trial for patients with metastatic renal cell carcinoma who have progressed on prior treatment with a PD-1/PD-L1 immune checkpoint inhibitor.

Novel Immunotherapy-Based Combinations Prompt Key Treatment Considerations in RCC

November 4th 2022

Bradley McGregor, MD, discusses the factors that affect frontline treatment decisions for patients with advanced RCC, the importance of longer-term follow-up of phase 3 trials in kidney cancer, and the benefits of dual immunotherapy and immunotherapy/TKI treatment combinations.

Novel Trial Designs and Modern Research Efforts Drive RCC Treatment Advances

November 4th 2022

Eric Jonasch, MD, discusses key clinical trials that are paving the way for improved treatment sequencing in renal cell carcinoma and the prospective benefits of neoadjuvant cabozantinib in nonmetastatic clear cell renal cell carcinoma.

Surgical Delays Caused By COVID-19 Do Not Increase Risk of pT3a Upstaging, Compromise OS in cT1b-cT2b RCC

November 9th 2020

The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.

Clinical Activity, Safety of Modified Nivolumab/Ipilimumab Dose in RCC Confirm Best Practices

November 7th 2020

A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.

Future of VHL Disease–Associated RCC Bright, With Immunotherapy and HIF-2α, CDK4/6 Inhibitors Part of Ongoing Research

November 7th 2020

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.

Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner

November 7th 2020

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Dr. Vaishampayan on the Expanding Role of TKI/Immunotherapy Combinations in mRCC

November 6th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

November 6th 2020

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.